Neoadjuvant therapy for pancreas cancer: Global perspective and optimal care pathways in low to middle-income countries
- PMID: 33831251
- DOI: 10.1002/jso.26365
Neoadjuvant therapy for pancreas cancer: Global perspective and optimal care pathways in low to middle-income countries
Abstract
Surgery remains the only curative intent treatment modality for localized pancreatic adenocarcinoma. Even in those who can undergo successful margin negative resection, the ability to deliver adjuvant chemotherapy is suboptimal for various reasons, resulting in poor outcomes. The delivery of "standard of care" intensive modern neoadjuvant therapies can be challenging in low to-middle-income countries (LMICs) with limited resource. This article reviews the constraints in delivering neoadjuvant therapies in LMICs and strategies to improve its implementation.
Keywords: borderline resectable; global perspective; low to middle income countries; neoadjuvant therapy; pancreatic cancer.
© 2021 Wiley Periodicals LLC.
Similar articles
-
Ten-year experience in optimizing neoadjuvant therapy for localized pancreatic cancer-Medical college of Wisconsin perspective.J Surg Oncol. 2021 May;123(6):1405-1413. doi: 10.1002/jso.26395. J Surg Oncol. 2021. PMID: 33831252 Review.
-
Efficacy of Neoadjuvant Radiotherapy After Chemotherapy and the Optimal Interval from Radiotherapy to Surgery for Borderline Resectable and Resectable Pancreatic Cancer.Ann Surg Oncol. 2025 Apr;32(4):2819-2829. doi: 10.1245/s10434-024-16743-2. Epub 2025 Jan 14. Ann Surg Oncol. 2025. PMID: 39808212 Free PMC article.
-
Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma.J Surg Oncol. 2021 May;123(6):1432-1440. doi: 10.1002/jso.26384. J Surg Oncol. 2021. PMID: 33831253 Review.
-
A review of response in neoadjuvant therapy for exocrine pancreatic cancer.J Surg Oncol. 2021 May;123(6):1449-1459. doi: 10.1002/jso.26369. J Surg Oncol. 2021. PMID: 33831249 Review.
-
Neoadjuvant therapy versus upfront surgery for borderline-resectable pancreatic cancer.Minerva Chir. 2020 Feb;75(1):15-24. doi: 10.23736/S0026-4733.19.07958-6. Epub 2019 May 20. Minerva Chir. 2020. PMID: 31115240
Cited by
-
Correlation between Angiotensin Inhibitor Administration and Longer Survival in Patients Who Underwent Curative Resection for Pancreatic Cancer.Yonsei Med J. 2024 Jun;65(6):324-331. doi: 10.3349/ymj.2023.0399. Yonsei Med J. 2024. PMID: 38804026 Free PMC article.
-
Identification of the Biosynthetic Gene Cluster of New Piperazic Acid-Containing Lipopeptides with Cytotoxic Activity in the Genome of Marine Streptomyces PHM034.Metabolites. 2023 Oct 18;13(10):1091. doi: 10.3390/metabo13101091. Metabolites. 2023. PMID: 37887416 Free PMC article.
-
Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma.JAMA Surg. 2025 Feb 1;160(2):172-180. doi: 10.1001/jamasurg.2024.5191. JAMA Surg. 2025. PMID: 39630427
References
REFERENCES
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
-
- GBD. Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2017;2019(4):934-947.
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7-30.
-
- Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer; Available from: https://gco.iarc.fr/today, Accessed 20 November 2020.
-
- Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019;10:10-27.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical